AGC BIOLOGICS BAGS TRANSATLANTIC AWARD FOR INVESTMENTS IN MILAN BIOPHARMACEUTICAL INDUSTRY

KUALA LUMPUR, Dec 21 (Bernama) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham).

The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes expansion at its Center of Excellence in Milan to make it a global hub for cell and gene therapy innovation, development and manufacturing.

Luca Alberici, AGC Biologics General Manager and Site Head of the Milan facility, received the award on behalf of the company during the XV Transatlantic Award Gala Dinner on Dec 2 at Studio 90 East End Studios in Milan, according to a statement.

“I am happy and honoured to receive this award on behalf of AGC Biologics. This is an important award that showcases the investments our company has made in our Milan site, as well as the growing biopharmaceutical industry in our region,” said Alberici.

“Our Center of Excellence, one of the best in world and our team of scientists and employees, who work hard every day with responsibility and professionalism, played a crucial role in the successes we’ve achieved over the last two years.”

The additional guests of honour at the award ceremony included Mariangela Zappia (AmCham Italy Honorary President and Ambassador of Italy to the United States of America), Thomas D. Smitham (Chargé d’Affaires and interim and U.S. Embassy to Italy), On. Giancarlo Giorgetti (Italian Minister of Economic Development) and On. Lorenzo Guerini (Italian Minister of Defense).

AGC Biologics was honoured alongside other notable companies such as Apple, Coca-Cola, Diasorin and KKR.

AGC Biologics acquired the Milan facility when it purchased Molecular Medicine S.p.A. (MolMed) in 2020. Since that transaction, AGC Biologics has focused on supporting and developing the teams working at the site, and investing in expanding the site’s services, capabilities and production capacities.

These commitments in the Milan facility have helped AGC Biologics become one of the most complete and active biotech CDMOs in the global healthcare market.

More details at www.agcbio.com.

-- BERNAMA